AME — AMETEK, Inc.

As of 2026-09-13, sentiment is bullish on the back of the 2026-08-04 Q2 report: revenue +15% y/y to a record $2.04B, adjusted EPS $2.09 (+17%), adjusted operating margin 26.6%, and orders +28% y/y. Analysts responded by raising targets (Truist to $316, KeyBanc to $295, BMO to $282, TD Cowen to $275), and the consensus is Buy with 20 Buy/10 Hold/0 Sell. The stock's 6.4% one-month decline as of 2026-09-13 looks like profit-taking after a strong six-month run (+12.8%) rather than a change in the fundamental narrative.

Revenue marched from $1.62B in Q3 2023 to $2.04B in Q2 2026, with YoY growth reaccelerating: +10.8% in Q3 2025, +13.5% in Q4 2025, +11.3% in Q1 2026, and +15.0% in Q2 2026. Gross margin has held in the 36-37% range, while operating margin is roughly 25-27%. GAAP diluted EPS rose from $1.47 in Q3 2023 to $1.77 in Q2 2026, and management reported record adjusted EPS of $2.09, up 17% y/y. Free cash flow is consistently positive—TTM FCF is about $1.82B versus TTM net income of $1.58B—so cash conversion remains a strength. The 28% order growth and raised full-year guidance suggest the recent acceleration is not just a one-quarter blip.

Expensive relative to its own history. As of 2026-09-13, the TTM P/E is 35.2x versus a 5-year average of 30.64x, P/S is 7.05x versus a 5-year average of 5.91x, and the PEG is 3.37. The forward P/E is about 29.0x on next-FY EPS of $8.339, which is only a modest discount to the historical trailing average. The dividend yield is thin at 0.56%. A premium is justified by quality and low leverage, but the stock already discounts continued double-digit growth and margin expansion.

As of 2026-09-13, the $241.87 price implies roughly 29x next-FY EPS of $8.339. That multiple requires AMETEK to keep delivering high-single-to-low-double-digit EPS growth and incremental margin expansion, which the 28% order growth supports. If Q3 2026 revenue conversion or margins disappoint, the multiple has room to compress toward the low-20s, implying downside toward the high-$180s/low-$200s. Conversely, a clean Q3 beat-and-raise could push the stock back toward the analyst consensus near $271. The risk/reward is roughly balanced at this price.

As of 2026-09-13, RSI was 52.1—neutral, not overbought or oversold. The price was barely above its 20-day (+0.53%) and 50-day (+0.25%) moving averages but 6.6% above its 200-day SMA, so the intermediate trend is still up. The one-month return was -6.44%, while three- and six-month returns were +6.49% and +12.77%, indicating a consolidation/pullback within an uptrend. Entry timing is neutral: there is no technical washout, but the stock is not extended either. A pullback toward the 200-day SMA would offer a better risk/reward than chasing the current bounce.

• Elevated interest rates continue to pressure industrial valuations and raise the discount rate applied to long-duration compounders like AMETEK.
• Aerospace/defense and medical/diagnostics spending remain secular tailwinds for EIG and EMG, supporting niche demand.
• Data-center infrastructure buildout is lifting demand for power management and thermal solutions.
• Tariff and trade policy uncertainty could disrupt global component supply chains and input costs, though AMETEK has so far protected margins.
• A strong balance sheet and investment-grade capacity position AMETEK to keep executing bolt-on M&A, but a higher-rate environment raises the bar for deal returns.

• Q3 2026 earnings in late October/early November 2026: watch whether 28% order growth converts into backlog and organic revenue acceleration.
• M&A announcements from AMETEK's active bolt-on pipeline, which could add growth but also integration risk.
• Further analyst target revisions after Q3; consensus target is $271.36 with recent average $281.67.
• Potential easing of interest rates or trade tensions, which would benefit high-multiple industrials.

• Valuation risk: 35.2x TTM P/E and 7.05x sales versus 5-year averages of 30.64x and 5.91x leave little room for execution missteps.
• Industrial cyclicality: a broader manufacturing slowdown could cut orders and delay backlog conversion.
• Tariffs and supply-chain disruptions could pressure gross margins, which are only ~36%.
• M&A integration risk and potential overpayment as AMETEK deploys its strong balance sheet.
• GAAP margins and ROIC (11%) are good but not elite; the premium multiple depends on sustained adjusted-margin expansion.

AMETEK is a high-quality, well-managed industrial compounder with a pristine balance sheet, consistent free cash flow, and an accelerating top line. But as of 2026-09-13 the stock trades at a rich 35.2x TTM earnings and 29x forward earnings, well above its own historical sales multiple, so much of the good news is already priced in. I would not chase it here; the risk/reward is balanced, and a pullback toward the low-$200s would be a more attractive entry point.

I applied a 30.0x forward P/E to next-FY consensus EPS of $8.339. The 30x multiple is a slight discount to AMETEK's 5-year average trailing P/E of 30.64x, reflecting its premium quality, low leverage, and double-digit order growth, but also the rich absolute valuation and 3.37 PEG. That yields a fair value of $250.17.